BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 35787693)

  • 1. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
    Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
    J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
    Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
    J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
    Sholler DJ; Zamarripa CA; Spindle TR; Martin EL; Kuntz D; Vandrey R; Grabenauer M
    J Anal Toxicol; 2022 Oct; 46(8):882-890. PubMed ID: 35770374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study.
    Varadi G; Zhu Z; Crowley HD; Moulin M; Dey R; Lewis ED; Evans M
    Adv Ther; 2023 Jan; 40(1):282-293. PubMed ID: 36308640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
    Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Action and Pharmacokinetics of Cannabis.
    Chayasirisobhon S
    Perm J; 2020 Dec; 25():1-3. PubMed ID: 33635755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol, ∆
    Pigliasco F; Malaca S; Lo Faro AF; Tini A; Cangemi G; Cafaro A; Barco S; Riva A; Pisati A; Amadori E; Striano P; Tagliabracci A; Huestis MA; Busardò FP
    Front Pharmacol; 2022; 13():1038754. PubMed ID: 36353497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated method for the simultaneous quantification of cannabidiol, Δ
    Kevin RC; Vogel R; Doohan P; Berger M; Amminger GP; McGregor IS
    Drug Test Anal; 2021 Mar; 13(3):614-627. PubMed ID: 33095968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic of two oral doses of a 1:20 THC:CBD
    Lyons C; McEwan K; Munn-Patterson M; Vuong S; Alcorn J; Chicoine A
    Front Vet Sci; 2024; 11():1352495. PubMed ID: 38585296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UHPLC-MS-MS Determination of THC, CBD and Their Metabolites in Whole Blood of Light Cannabis Smokers.
    Lo Faro AF; Tini A; Gottardi J; Pichini S; Carlier J; Giorgetti R; Busardò FP
    J Anal Toxicol; 2023 Jan; 46(9):e256-e261. PubMed ID: 36214389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.